# TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

> **NCT03745651** · PHASE3 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 618 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Ruxolitinib cream
- **DRUG:** Vehicle cream

## Key facts

- **NCT ID:** NCT03745651
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-20
- **Primary completion:** 2019-11-18
- **Final completion:** 2020-11-09
- **Target enrollment:** 618 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745651, "TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03745651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*